Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
Actinic Keratosis
DRUG: GDC 695|DRUG: Diclofenac Sodium Gel, 3%|DRUG: Vehicle gel
Number of Subjects With Complete Clearance of AK Lesions, Complete Clearance was defined as 100% clearance of all Actinic Keratosis (AK) lesions (having a count of zero AKs) in the treatment area (face or bald scalp) at the Day 90 visit (30 Days Post Treatment)., Day 90 (30 days after completion of 60 days of treatment)
Adverse Events (AEs), AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported., Day 0 through Day 90
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.